Page last updated: 2024-08-23

etoposide and Communicable Diseases

etoposide has been researched along with Communicable Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Fukuhara, N; Imaizumi, Y; Izutsu, K; Matsuda, S; Miyazaki, K; Nakazato, T; Shimada, K; Suehiro, Y; Suzuki, R; Suzumiya, J; Takahashi, T; Tomita, N; Yamaguchi, M; Yoshida, I	1

Other Studies

1 other study(ies) available for etoposide and Communicable Diseases

Article	Year
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. International journal of hematology, 2020, Volume: 112, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Multicenter Studies as Topic; Prednisone; Retrospective Studies; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine; Young Adult	2020

Article

Year

Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.

International journal of hematology, 2020, Volume: 112, Issue:6

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Multicenter Studies as Topic; Prednisone; Retrospective Studies; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine; Young Adult

2020